This article was downloaded by:

On: 27 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713618290

Carbovir-Related Compounds and Phosphonate Analogues

Phuong -T. Phama; Robert Vinceb

^a Penn State Worthington Scranton, Dunmore, PA ^b Center for Drug Design, Academic Health Center, and Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN

To cite this Article Pham, Phuong -T. and Vince, Robert (2007) 'Carbovir-Related Compounds and Phosphonate Analogues', Phosphorus, Sulfur, and Silicon and the Related Elements, 182: 4, 779 - 791

To link to this Article: DOI: 10.1080/10426500601047578 URL: http://dx.doi.org/10.1080/10426500601047578

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Phosphorus, Sulfur, and Silicon, 182:779-791, 2007

Copyright © Taylor & Francis Group, LLC ISSN: 1042-6507 print / 1563-5325 online

DOI: 10.1080/10426500601047578



Carbovir-Related Compounds and Phosphonate Analogues

Phuong-T. Pham

Penn State Worthington Scranton, Dunmore, PA

Robert Vince

Center for Drug Design, Academic Health Center, and Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN

Detailed syntheses of carbovir-related cis-[2-(9H-Purin-9-yl)-3-cyclopentene]-1-methanols and phosphonates of selected analogues are presented. Our interest in this chemistry stems from antiviral activity shown by closely related compounds. Access to the key β -lactam was achieved by the reaction of monocyclopentadiene with chlorosulfonyl isocyanate at -78° C rather than at the reported ambient temperature, where only the less ring-strained and more stable γ -lactam is formed.

Keywords Carbocyclic nucleosides; carbovir triphosphate; HIV reverse transcriptase; lactam

INTRODUCTION

Although many nucleoside derivatives designed to target viral reverse transcriptase have been synthesized, only a handful have been marketed for use in combinational therapeutic treatment of AIDS.^{2,3} A series of carbocyclic nucleosides originated from our laboratory has led to the development of a clinically useful drug. These carbocyclic 2',3'-didehydro-2',3'-didehydro-2',3'-didehydro-2',3'-dideoxyguanosine (carbovir 1a), is enzymatically converted to the active form, carbovir triphosphate, which inhibits HIV reverse transcriptase. All other active derivatives in this series are ultimately converted to the same active metabolite. Thus, the anti-HIV drug derived

Received July 12, 2006; accepted August 29, 2006.

Address correspondence to Phuong-T. Pham, Penn State Worthington Scranton, 120 Ridge View Drive, Dunmore, PA 18707. E-mail: ptp2@psu.edu

1a, carbovir, X = OH1b, abacavir, $X = HN - \triangleleft$

2a, R = H**2b**, $R = (HO)_2 P(O) CH_2$

SCHEME 1

from this series, abacavir **1b** (ZiagenTM), derives its activity via conversion to carbovir triphosphate (Scheme 1).

Nevertheless, the continuous need for new anti-HIV agents arises from the development of drug resistance as well as toxicity after prolonged use of the nucleosides.^{6,7} We report herein the syntheses of a series of novel carbovir-related carbocyclic nucleosides (**2a**), in which the 4'hydroxymethyl group was replaced by a 5' hydroxymethyl. Phosphonates of selected analogs (**2b**) were also prepared as the introduction of phosphonate in the design of more useful antiviral agents have been well documented.^{8–10}

DISCUSSION

The key in preparing our title compounds **2a** and derivatives was to obtain 2-azabicyclo[3.2.0]hept-3-en-7-one, β -lactam (**3a**).

The reaction of chlorosulfonyl isocyanate and cyclopentadiene at ambient temperature was found to give 2-azabicyclo[2.2.1]hept-5-en-3-one, γ - or Vince Lactam (**3b**), rather than the reported $^1\beta$ -lactam (**3a**). To obtain the desired β -lactam, the reaction temperature had to be lowered significantly. When the reaction temperature was lowered between -5 and -10° C, β -lactam began to form resulting in a mixture of lactams. At -78° C the reaction proceeded to give selectively β -lactam, following treatment with sodium sulfite (Scheme 2). 1 H NMR spectra for both lactams agreed well with reported literature values. 1,11 While δ values for the methylene hydrogens of γ -lactam were found between 2.39–2.18 ppm, the reported shifts were 2.38–2.20 ppm. The δ values for the allylic methylene hydrogens of β -lactam were found to be slightly more downfield between 2.67–2.33 ppm. These values are again comparable with the reported chemical shifts of 2.68–2.38 ppm. This downfield

SCHEME 2 Reaction conditions yielding β - and γ -lactams.

shift reflects the proximity of the two hydrogens to the double bond in β -lactam.

Synthetic routes for the preparations of compounds **8** and **12–14** starting from cis (\pm) mixture of β -lactam isomers are outlined in Scheme 3. Thus, hydrolysis of (3a) with methanolic HCl followed by reduction with calcium borohydride provided the amino alcohol **5** (63%). Coupling of **5** with 5-amino-4,6-dichloropyrimidine and

SCHEME 3 (a) 1N HCl/MeOH, reflux; (b) $Ca(BH_4)_2$, THF; (c) 5-amino-4,6-dichloropyrimidine, Et_3N , BuOH, reflux; (d) $(EtO)_3CH$, HCl, aq. 0.5 N HCl; (e) liquid NH_3 , 65° ; (f) 2-amino-4,6-dichloropyrimidine, Et_3N , BuOH, reflux; (g) 4- $ClC_6H_4N_2^+Cl^-$, HOAC, aq. NaOAc; (h) Zn, aq. HOAC, $EtOH/H_2O$, reflux; (i) 1 N HCl; (j) liquid NH_3 , $80^\circ C$; (k) cyclopropylamine/EtOH, reflux.

2-amino-4,6-dichloropyrimidine in the presence of triethylamine furnished intermediates $\bf 6$ and $\bf 9$, respectively. Diazotization of $\bf 9$ was carried out with 4-chlorophenyldiazonium chloride at 65° C rather than 25° C due to the insolubility of the starting material at lower temperature. A mixture of $\bf 9$ and NaOAc in $\rm H_2O/acetic$ acid was heated to 65° C for 20 minutes before the diazonium reagent was added. Compound $\bf 10$ was obtained in good yield (89%). Reduction of $\bf 10$ with zinc-acetic acid afforded the 2,5-diamino-6-chloro-4-pyrimidinyl product $\bf 11$.

Compounds **6** and **11** were converted to the corresponding 9-substituted-6-chloropurine **7** and 2-amino-6-chloro-9-purin-9-yl **12** by ring closure with triethylorthoformate under acidic conditions followed by mild acid hydrolysis. Compounds **8** and **14** were obtained by reaction of the corresponding 6-chloro intermediates with liquid ammonia under pressure.

Treatment of **12** with 1N HCl at 65° C for 5 h gave **13** in a moderate yield of 67%. The 6-cyclopropylamine analogue **15** was obtained by the reaction of **12** with excess cyclopropylamine in ethanol under pressure at $65-70^{\circ}$ C. ¹²

Phosphonate analogues of 6-aminopurine (16), 6-hydroxy-2-aminopurine (17), and 6-cyclopropylamine-2-aminopurine (18) were obtained by reaction of the corresponding alcohols with diethyl phosphonomethyltriflate in the presence of NaH. The yields of these reactions were rather poor (20%). Hydrolysis of the phosphonate esters were carried out using Bromotrimethyl Silane (BTMS) followed by treatment with $\rm H_2O$ (Scheme 4). $\rm ^{31}P$ NMR showed that while these phosphonate esters resonate around 22 ppm, their corresponding acids shifted upfield by about 2.7 ppm. Proton-phosphorus coupling of 2 Hz was observed in $\rm ^{1}H$ NMR spectra of esters 17a and 18a. This long-range coupling ($\rm ^{4}\textit{J}_{PH}$) has been previously reported in the literature $\rm ^{13}$ with values of 2.4 to 3.2 Hz.

8, 13, 15
$$\frac{1. \text{ NaH/THF, } 20^{\circ}\text{C}}{2. \text{ (EtO)}_{2}\text{P(O)}\text{CH}_{2}\text{OSO}_{2}\text{CF}_{3}}$$

EtO

EtO

N

N

N

HO

HO

N

N

Y

16b, $X = \text{NH}_{2}$; $Y = \text{H}$

17a, $X = \text{OH}$; $Y = \text{NH}_{2}$

18a, $X = \text{HN} \triangleleft$; $Y = \text{NH}_{2}$

18b, $X = \text{HN} \triangleleft$; $Y = \text{NH}_{2}$

18b, $X = \text{HN} \triangleleft$; $Y = \text{NH}_{2}$

CONCLUSION

In conclusion, the synthesis of a series of novel carbovir-related compounds was achieved from the key β -lactam, 2-azabicyclo[3.2.0]hept-3-en-7-one, to give a racemic mixture of the desired carbocyclic nucleosides and selected phosphonate analogues. The key step in the described synthetic strategy is based on a newly modified method to selectively access the key intermediate β -lactam.

EXPERIMENTAL

General

All reagents and anhydrous solvents were obtained from Sigma-Aldrich. BTMS was distilled before use. Diethyl phosphonomethyltri-flate was prepared by the reaction of trifluoromethane sulfonyl chloride with diethylhydroxymethyl phosphonate following the procedure described by Phillion and Andrew. Diethylhydroxymethyl phosphonate was prepared by the reaction of diethylphosphite with paraformal dehyde in the presence of triethylamine under reflux condition. 10

¹H and ³¹P NMR spectra were recorded on a Varian 300 instrument. Chemical shifts are reported relative to external Me₄Si, internal CDCl₃, or external 85% H₃PO₄ (³¹P). TLC was done on E. Merck (Darmstadt, Germany) silica gel (0.25 mm thickness) 60F-254 glass plates. Plates were visualized using 5% phosphomolybdic acid in EtOH. Elemental analyses were performed by M-H-W Laboratories, Phoenix, AZ.

2-Azabicyclo[2.2.1]hept-5-en-3-one (3b)

A solution of freshly distilled cyclopentadiene (4.50 g, 68.1 mmol) in anhydrous CH_2Cl_2 (10 mL) was added to a solution of chlorosulfonyl isocyanate (5.25 mL, 8.50 g, 60.3 mmol) in CH_2Cl_2 (90 mL) over a period of 20 min at ambient temperature. After the complete addition, the reaction was continued stirring for 10 min and then quenched with a solution of sodium sulfite (20 g/80 mL H_2O). The CH_2Cl_2 layer was separated, and the aqueous layer was extracted with CH_2Cl_2 (2 × 150 mL). Combined organic layers were dried and concentrated to give a crude brown oil (1.80 g, 32.0%). ¹H NMR identified the product as **3b**. NMR values obtained were identical with those reported for γ -lactam. ¹H NMR ($CDCl_3$, 300 MHz): δ 6.82–6.73 (m, 1H, C6H=C), 6.68–6.62 (m, 1H, C=C5H), 6.3 (broad s, 1H, NH), 4.33 (s, 1H, C1-H), 3.20 (s, 1H, C4-H), 2.39–2.18 (m, 2H, C7-H2).

6-Azabicyclo[3.2.0] hept-3-en-7-one (3a)

A solution of freshly distilled cyclopentadiene (9.3 g, 140.8 mmol) in anhydrous CH_2Cl_2 (10 mL) was added dropwise (15 min) to a solution of chlorosulfonyl isocyanate (14.6 g, 9.0 mL, 103.4 mmol) in CH_2Cl_2 (300 mL) at $-78\,^{\circ}C$. The reaction mixture was continued stirring for 4 h with cooling and was then added in portion to an aqueous solution of Na_2SO_3 (60 g/200 mL H_2O). After 30 min of stirring at ambient temperature, the organic layer was separated and taken up in MeOH (200 mL) and dried over MgSO_4. Removal of the solvent gave crude yellow oil ($R_f=0.65$, $CHCl_3:MeOH,5:1$), which was further purified by flash chromatography ($CH_2Cl_2:MeOH,300:5$) to give 6.70 g of 3a (59%). 1H NMR ($CDCl_3,300$ MHz): δ 6.92 (broad s, 1H, NH), 5.98–5.95 (m, 1H, C4H=C), 5.94–5.88 (m, 1H, C=C3H), 4.43 (broad s, 1H, C5-H), 3.76–3.73 (m, 1H, C1-H), 2.67–2.33 (m, 2H, $C2-H_2$).

Cis-(+)-Methyl-(2-aminocyclopent-3-ene)1-carboxylate Hydrochloride (4)

6-azabicyclo[3.2.0]hept-3-en-7-one **3a** (6.42 g, 58.8 mmol) was dissolved in 1N methanolic HCl (150 mL) and refluxed for 3 h. The solvent was then removed in vacuo and the residue chromatographed (ETOAc: MeOH) on a silica gel column to give **4** as an off-white solid, m.p. 181–182°C: 5.59 g (68%). MS (FAB): m/e 142 (M⁺ +1). ¹H NMR [(CD₃)₂SO, 300 MHz]: δ 8.19 (broad s, 2H, NH₂), 6.16–6.14 (m, 1H, C3H=C), 5.60–5.77 (m, 1H, C=C4H), 4.27 (d, 1H, C2H, J = 8 Hz), 3.66 (s, 3H, CH₃O), 3.49–3.40 (m, 1H, C1H), 2.82–2.53 (m, 2H, C5H₂). Anal. calcd. (C₇H₁₁NO₂.HCl.1/8 CH₃OH): C, 47.12; H, 7.22; N, 7.72; found: C, 47.46; H, 7.46; N 7.73.

Cis-(+) -[2-(5-Amino-6-chloro-4-pyrimidinyl)-amino-cyclopent-3-ene]1-methanol (6)

A suspension of finely grounded CaCl₂ (7.16 g. 64.5 mmol) and NaBH₄ (4.88 g, 129 mmol) in anhydrous THF (400 mL) was stirred at r.t. for 1.5 h. To the suspension was added a solution of 4 (5.0 g, 28 mmol) in anhydrous THF (200 mL), and the reaction mixture was stirred for 20 h at r.t. The reaction was quenched by adding H₂O until bubbling ceased. The resulting salt was filtered off and washed with ethanol. The filtrate was concentrated and azeotroped several times with absolute EtOH to give a brown syrup, identified by ¹H NMR as the amino alcohol 5 (2.0 g, 63%), and was used in the following reaction without further purification. ¹H NMR (CDCl₃, 300 NHz): δ 6.12–6.11 (m, 1H, C3H=C), 5.88–5.86 (m, 1H, C=C4H), 5.67 (broad s, 2H, NH₂),

4.33 (d, 1H, C2H, J = 2Hz), 3.90-3.78 (m, 2H, CH₂OH), 3.41-3.25 (m, 1H, C1H), 2.50-2.48 (m, 2H, C5H₂).

A solution of **5** (3.0 g, 26.50 mmol), triethylamine (11 mL), and 5-amino-4,6-dichloropyrimidine (4.16 g, 25.4 mmol) in n-butanol (150 mL) was refluxed at 110°C for 24 h. Excess solvent was removed in vacuo, and the residue was chromatographed on a silica gel column (EtOAc:hexane). Product **6** was obtained as an off-white solid: (4.1 g, 64%), m.p. 120–124°C. MS (FAB): m/e 241 (M⁺ +1), 239 (M⁺ -1). 1 H NMR [(CD₃)₂SO, 300 MHz]: δ 7.72 (s, 1H, C2'H), 6.50 (d, 1H, NH, J= 8 Hz), 5.98–5.96 (m, 1H, C3H=C), 5.72–5.71 (m, 1H, C=C4H), 5.28–5.24 (m, 1H, C2H), 5.08 (broad s, 2H, NH₂), 4.31–4.27 (m, 1H, OH), 3.64–3.20 (m, 3H, CH₂OH and C1H), 2.48–2.25 (m, 2H, C5H₂). Anal. calcd. (C₁₀H₁₃N₄OCl): C, 49.90; H, 5.44; N, 23.28; found: C, 50.12; H, 5.57; N, 23.35.

Cis-(+)-[2-(6-Chloro-9H-purin-9-yl)cyclopent-3-ene]1-methanol (7)

A solution of **6** (3.0 g, 13 mmol) in triethyl orthoformate (75 mL) and conc. HCl (0.75 mL) was stirred overnight at r.t. The reaction mixture was then concentrated under pressure, and the residue was stirred in 0.5 N HCl (20 mL) for 3 h. The resulting aqueous solution was neutralized to pH \sim 7–8 with 1N NaOH, concentrated in vacuo, and azeotroped with absolute EtOH. The residue was chromatographed (EtOAc:MeOH) on a silical gel column to a give white solid **7** (1.08 g, 35%), m.p. 158–160°C. MS (FAB): m/e 251 (M++1). ^1H NMR [(CD_3)_2SO, 300 MHz]: δ 8.76, 8.41 (each s, each 1H, C2'H and C8'H), 6.33–6.32 (m, 1H, C3H=C), 5.09–5.90 (m, 1H, C=C4H), 5.81–5.78 (m, 1H, C2H), 4.25 (broad s, 1H, OH), 3.15–2.70 (m, 2H, CH_2OH and 1H, C1H), 2.60–2.42 (m, 2H, C5H_2). Anal. calcd. (C11H11N4 ClO): C, 52.91; H, 4.42; N, 22.35; found: C, 52.91; H, 4.22; N, 22.69.

Cis-(+)-[2-(6-amino-9H-purin-9-yl)cyclopent-3-ene]-1-methanol (8)

A solution of **7** (850 mg, 3.4 mmol) in absolute MeOH (20 mL) was transferred to a stainless-steel bomb, and excess liquid NH₃ was added. The bomb was sealed and heated in an oil bath at 65°C for 20 h. Volatiles were removed, and the residue was purified by flash chromatography (CHCl₃/MeOH) to give the desired product as an off-white solid (714 mg, 91%), m.p. 184–186°C. ¹H NMR [(CD₃)₂SO, 300 MHz]: δ 8.11, 7.81 (each s, each 1H, C2′H and C8′H), 7.19 (broad s, 2H, NH₂), 6.29–6.27 (m, 1H, C3H=C), 5.90–5.88 (m, 1H, C=C4H), 5.60 (d, 1H, C2H, J = 7 Hz), 4.35 (broad s, 1H, OH), 3.33–2.89 (m, 2H, CH₂OH), 2.63–2.75 (m,

1H, C1H), 2.60–2.40 (m, 2H, C5H₂). Anal. calcd. ($C_{11}H_{13}N_5O$): C, 57.13; H, 5.67; N, 30.28; found: C, 57. 31; H, 5.59; N, 30.35.

Cis-(+)-Methyl-[2-(6-amino-9H-purin-9-yl)cyclopent-3-ene]-1-diethylphosphonate (16a)

A suspension of **8** (700 mg, 3 mmol) and NaH (83 mg, 3.5 mmol) in anhydrous THF (150 mL) was stirred overnight at r.t. under a N₂ atmosphere. The reaction flask was cooled to -20° C, and 1.4 eq. of diethyl phosphonomethyl triflate (1.23 g, 4.10 mmol) in THF (50 mL) was added dropwise over 2 h. Stirring was continued for another 2 h and the reaction was quenched with MeOH. The solvent was removed in vacuo, and the residue was chromatographed to give light yellow oil (200 mg, 17%). ¹H NMR (CDCl₃, 300 MHz): δ 8.29, 7.65 (each s, each 1H, C2'H and C8'H), 6.52 (s, 2H, NH₂), 6.28–6.27 (m, 1H, C3H=C), 5.83–5.81 (m, 1H, C=C4H), 5.72 (d, 1H, C2H, J = 7Hz), 4.07–3.93 (m, 4H, OC H₂CH₃), 3.38–3.05 (m, 4H, CH₂OC and P[O]C H₂), 3.00–2.90 (m, 1H, C1H), 2.70–2.80 (m, 2H, C5H₂), 1.24–1.18 (m, 6H, OCH₂C H₃). ³¹P NMR, proton coupled (CDCl₃, 300 MHz): δ 21. 99 (m). Anal. calcd. (C₁₆H₂₄N₅O₄P.1/2 H₂O): C, 49.23; H, 6.46; N, 17.94; found: C, 49.40; H, 6.44; N, 17.83.

Cis-(+)-Methyl-[2-(6-amino-9H-purin-9-yl)cyclopent-3-ene]-1-phosphonic Acid (16b)

Diethyl phosphonate ester **16a** (100 mg, 0.3 mmol) was dissolved in anhydrous acetonitrile (20 mL), and freshly distilled bromotrimethyl silane (1.0 mL) was added. The reaction mixture was stirred under N_2 at r.t. for 24 h. Excess BTMS and solvent were removed under reduced pressure. The grayish residue was dissolved in cold $\rm H_2O$ (1 mL), and acetone was added dropwise until a white precipitate was formed. Recrystallization with $\rm H_2O$:acetone (\sim 1:4) gave a white solid (45 mg, 52%), m.p. 218–220°C. MS (FAB): m/e 326 (M+ +1), 324 (M+ -1). $^{1}\rm H$ NMR [(CD₃)₂SO, 300 MHz]: δ 8.16, 7.90 (each s, each 1H, C2'H and C8'H), 7.39 (broad s, 2H, NH₂), 6.31 (broad s, 1H, C3H=C), 5.82 (broad s, 1H, C=C4H), 5.61 (broad s, 1H, C2H), 3.20–2.89 (m, 4H, C H₂OC and P[O]C H₂), 2.90–2.80 (m, 1H, C1H), 2.40–2.20 (m, 2H, C5H₂). $^{31}\rm P$ {1H} NMR [(CD₃)₂SO, 300 MHz]: δ 19.12 ppm. Anal. calcd. (C₁₂H₁₆N₅O₄.1/2H₂O): C, 43.11; H, 5.13; N, 20.95; found: C, 43.08; H, 4.48; N, 21.05.

Cis-(\pm)-2-[(2,5-Diamino-6-chloropyrimidin-4-yl)-amino] cyclopent-3-enyl Methanol (9)

A mixture of **5** (3.15 g, 27.8 mmol), 2-amino 4,6-dichloropyrimidine (4.80 g, 29.0 mmol), and triethylamine (7.5 mL) in n-butanol (250 mL) was refluxed for 48 h. The solvent was evaporated in vacuo, and the

residue was chromatographed (ETOAc:MeOH) to give the desired product $\bf 9$ as an off-white solid (1.0 g, 14%), m.p. 210–212°C. MS(FAB): m/e 241 (M++1). $^1{\rm H}$ NMR [(CD_3)_2SO, 300 MHz]: δ 6.20 (d, 1H, NH, J=8 Hz), 5.96–5.94 (m, 1H, C3H=C), 5.72–5.89 (m, 1H, C=C4H), 5.66 (broad s, 2H, NH_2), 5.13 (broad s, 1H, C2H), 4.36 (broad s, 1H, OH), 3.94 (broad s, 2H, NH_2), 3.42–3.33 (m, 2H, CH_2OH), 3.32–3.23 (m, 1H, C1H), 2.48–2.25 (m, 2H, C5H_2). Anal. calcd. (C10H13N4OCl): C, 49.90; H, 5.44; N, 23.28; found: C, 49.77; H, 5.19; N, 23.10.

$Cis-(\pm)-[2-[2-amino-6chloro-5-[(4-chlorophenyl)azol]-4-pyrimidyl]-amino]-cyclopent-3-enyl Methanol (10)$

p-Chlorobenzenediazonium chloride was prepared by adding dropwise a solution of sodium nitrite (325 mg, 4.75 mmol) in H₂O (2.5 mL) to a solution of p-chloroaniline (575 mg, 4.50 mmol) in 3N HCl (10 mL) at 0°C. Freshly prepared p-chlorobenzenediazonium chloride was added dropwise to a the reaction mixture containing 9 (3.17 g, 13.2 mmol) and sodium acetate (25 g) in HOAc (25 mL)/H₂O (25 mL) at 65-70°C. Heating was removed following the complete addition, and the reaction mixture was stirred overnight at r.t. A yellow precipitate was obtained after suction filtration and washing of the solid with H₂O (1.4 g, 89%), R_{f} = 0.76 (CHCl₃:MeOH, 5:1), m.p. > 300°C. MS (FAB): m/e 379 (M+). ¹H NMR [(CD₃)₂SO, 300 MHz]: δ 10.39 (d, 1H, NH, J = 9 Hz), 7.68–7.53 (m, 4H, C6H4), 7.58 (broad s, 2H, NH₂), 6.00–5.97 (m, 1H, C3H=C), 5.80-5.77 (m, 1H, C=C4H), 5.35 (t, 1H, C2H, J = 9 Hz), 4.66 (t, 1H, OH J = 5 Hz), 3.52–3.37 (m, 2H, CH₂OH), 2.60–2.40 (m, 2H, C5H₂). Anal. calcd. (C₁₆H₁₆N₆Cl): C, 50.67; H, 4.25; N, 22.16; found: C, 50.52; H, 4.15; N, 21.96.

Cis- (\pm) -2-(2,5-diamino-6-Chloro-9H-purin-9-yl)cyclopent-3-enyl Methanol (11)

A mixture containing **10** (1.0 g, 2.6 mmol), acetic acid (4 mL), and zinc (1.80 g, 27.5 mmol) in EtOH (200 mL)/H₂O (100 mL) was refluxed for 2 to 3 h, and concentrated under reduced pressure. The residue was taken up in saturated NaHCO₃ (50 mL) and extracted with CHCl₃ (3 × 50 mL). The organic layers were combined, dried over MgSO₄, and evaporated to give a brown oil, which was further purified by flash chromatography (CH₂Cl₂: MeOH) on a silica gel column. The analytically pure product was obtained as an off-white solid (600 mg, 89%), R_f = 0.54 (CHCl₃:MeOH, 5:1), m.p. 158–160°C. MS (CI, 150°C): 256 (M⁺ +1), 243 (M⁺ -12), 241 (M⁺ -14). ¹H NMR [(CD₃)₂SO, 300 MHz]: δ 6.19 (d, 1H, NH, J = 8 Hz), 5.96–5.94 (m, 1H, C3H=C), 5.72–5.69 (m, 1H, C=C4H), 5.66 (broad s, 2H, NH₂), 5.13 (t, 1H, C2H, J = 7 Hz), 4.34 (broad s, 1H,

C1H), 2.48–2.22 (m, 2H, C5H₂). Anal. calcd. (C₁₀H₁₄N₄ClO): C, 46.97; H, 5.52; N, 27.39; found: C, 47.17; H, 5.55; N, 27.46.

Cis-(\pm)-2-(2-Amino-6-chloro-1-9H-dihydropurin-9-yl)cyclopent-3-enyl Methanol (12)

To a solution of 11 (800 mg, 3.13 mmol) in anhydrous DMF (10 mL) was added triethylorthoformate (50 mL) and conc. HCl (0.5 mL). The reaction mixture was stirred overnight at r.t. Excess solvent was removed under pressure. The residue was taken up in 0.5N HCl (30 mL) and stirred for 4 h. The solution was adjusted to pH \sim 8 with 1N NaOH and then extracted with $CHCl_3$ (3 × 50 mL). Combined $CHCl_3$ layers were dried over MgSO₄ and evaporated in vacuo. Further purification was carried out by flash chromatography (CH₂Cl₂:MeOH) to give an offwhite glassy solid (682 mg, 82%), $R_f = 0.51$ (CHCl₃:MeOH, 5:1); m.p. $138-142^{\circ}$ C. MS (EI, 150° C): m/e 266 (M⁺ +1), 267 (M⁺ +2), 268 (M⁺ +3), 232 (M⁺ -33). ¹H NMR [(CD₃)₂SO, 300 MHz]: δ 7.80 (s, 1H, C8'H), 6.89 (broad s, 2H, NH₂), 6.27–6.26 (m, 1H, C3H=C), 5.87–5.84 (m, 1H, C=C4H), 5.49 (broad d, 1H, C2H, J=7 Hz), 4.35 (t, 1H, OH, J=4 Hz), 3.06–3.02 (m, 2H, CH₂OH), 2.70–2.52 (m, 1H, C1H), 2.55–2.38 (m, 2H, C5H₂). Anal. calc'd. (C₁₁H₁₂N₅ClO.1/2 H₂O): C, 48.10; H, 4.77; N, 25.49; found: C, 48.14; H, 5.04; N, 25.66.

Cis- (\pm) -2-(2-Amino-1-9H-dihydropurin-6-9-yl)cyclopent-3-enyl Methanol (13)

A solution of **12** (280 mg, 1.1 mmol) in 1N HCl was heated to 65°C for 5 h and neutralized with 1N NaOH. The reaction mixture was concentrated, and the residue was applied through a silica gel column (EtOAc:MeOH) to give an off-white solid (175 mg, 67%), $R_f = 0.11$ (CHCl₃:MeOH, 5:1); m.p. 185° C began to dec w/o melt. MS (FAB): m/e 248 (M⁺ +1), 246 (M⁺ -1). ¹H NMR [(CD₃)₂SO, 300 MHz]: δ 10.77 (broad s, 1H, C=C4H), 5.31 (d, 1H, C2H, J=7 Hz), 4.41 (t, 1H, OH, J=7 Hz), 3.08–2.82 (m, 2H, CH₂OH), 2.61–2.52 (m, 1H, C1H), 2.40–2.22 (m, 2H, C5H₂). Anal. calcd. (C₁₁H₁₃N₅O₂): C, 53.44; H, 5.30; N, 28.33; found: C, 53.60; H, 5.52; N, 28.15.

Cis-(\pm)-2-(2,6-Diamino-1-9H-dihydropurin-6-9-yl)cyclopent-3-enyl Methanol (14)

Liquid ammonia was added to a solution of **12** (100 mg, 0.4 mmol) in absolute MeOH (15 mL); the bomb then was sealed and heated to 80°C for 48 h. Ammonia and methanol were evaporated, and the residue was chromatrographed on a silica gel column to give an off-white solid (53 mg, 57%), R_f = 0.22 (CHCl₃:MeOH, 5:1), m.p. 232–234°C. MS (FAB): m/e 247 (M⁺ +1). ¹H NMR [(CD₃)₂SO, 300 MHz]: δ .37 (s, 1H, C8'H), 6.70 (s,

2H, NH₂), 6.28–6.24 (m, 1H, C3H=C), 5.91–5.85 (m, 1H, C=C4H), 5.84 (broad s, 2H, NH₂), 5.87 (d, 1H, C2H, J=7 Hz), 4.48 (broad s, 1H, OH), 3.10–2.84 (m, 2H, CH₂OH), 2.68–2.59 (m, 1H, C1H), 2.42–2.25 (m, 2H, C5H₂). Anal. calc'd. (C₁₁H₁₄N₆O): C, 53.65; H, 5.73; N, 34.13; found: C, 53.30; H, 5.76; N, 33.91.

Cis-(\pm)-2-(2, 6-Cyclopropylamino-1-9H-dihydropurin-6-9-yl) cyclopent-3-enylmethanol (15)

To a solution of **12** (100 mg, 0.4 mmol) in absolute ethanol (20 mL) was added excess cyclopropylamine (1 mL). The bomb was sealed and heated to 65–70°C for 48 h. The volatiles were evaporated, and the residue was chromatographed on a silica gel column (CH₃Cl:MeOH) and recrystallized in CH₃CN to give a white solid (52 mg, 48%), R_f = 0.56 (CHCl₃:MeOH, 5:1), m.p. 168–170°C. MS (FAB): m/e 287 (M⁺ +1). ¹H NMR [(CD₃)₂SO, 300 MHz]: δ 7.36 (s, 1H, C8'H), 6.31–6.21 (m, 1H, C3H=C), 5.85 (broad s, 3H, C=C4H and NH₂), 5.40 (broad d, 1H, C2H, J = 7 Hz), 4.42 (broad s, 1H, OH), 3.20–2.28 (m, 2H, CH₂OH), 2.63–2.50 (m, 1H, C1H), 2.42–2.25 (m, 2H, C5H₂), 0.84–0.75 (m, 4H, CH₂CH₂). Anal. calcd. (C₁₄H₁₈N₆O): C, 58.73; H, 6.34; N, 29.35; found: C, 58.50; H, 6.41; N, 29.37.

Cis-(\pm)-Methyl-2-[(2-amino-1-9H-dihydropurin-6-on-9-yl) cyclopent-3-enylmethanol]-1-diethyl Phosphonate (17a)

A suspension of **13** (280 mg, 1.13 mmol) and NaH (81 mg, 3.4 mmol) in anhydrous THF (150 mL) was stirred at ambient temperature overnight under nitrogen. The suspension was cooled to -20° C, and diethylphosphonomethyl triflate (680 mg, 2.27 mmol) in THF (10 mL) was added dropwise. Stirring was continued for 4 h at -20° C, and 4° C overnight. Methanol was added to quench the reaction, and excess solvents were removed in vacuo. The residue was purified by flash chromatography on a silical gel column (EtOAc:MeOH) to give a white solid (95 mg, 21%), $R_f = 0.26$ (CHCl₃:MeOH, 5:1), m.p. 72–75°C. MS (FAB): m/e 398 (M⁺ +1), 396 (M⁺-1). ¹H NMR (CDCl₃): δ 10.60 (broad s, 1H, NH), 7.37 (s, 1H, C8'H), 6.49 (broad s, 2H, NH₂), 6.24–6.22 (m, 1H, C3H=C), 5.85– $5.83 \,(\text{m}, 1\text{H}, \text{C}=\text{C}4\text{H}), 5.38 \,(\text{d}, 1\text{H}, \text{C}2\text{H}, J = 7 \,\text{Hz}), 3.99 - 3.88 \,(\text{m}, 4\text{H}, \text{OC})$ H_2CH_3), 3.44–3.60 (m, 2H, P[O]CH₂), 3.22–3.00 (m, 2H, CH₂OC), 2.82– 2.71 (m, 1H, C1H), 2.58–2.42 (m, 2H, C5H₂), 1.16 (dt, 6H, OCH₂C H₃, ${}^{4}J_{PH} = 2 \text{ Hz}, {}^{3}J_{HH} = 7 \text{ Hz}.$ ${}^{31}P \text{ NMR}, \text{ proton coupled (CDCl}_{3}, 300 \text{ MHz}):$ $\delta 2.30$ (m). Anal. calcd. (C₁₆H₂₄N₅O₅P.2H₂O): C, 44.34; H, 6.61; N, 16.16; found: C, 44.28; H, 6.65; N, 15.76.

Cis- (\pm) -Methyl-2-[(2-amino-1-9H-didehydropurin-6-on-9-yl) cyclopent-3-enylmethanol]-1-phosphonic Acid (17b)

Diethyl phosphonate ester **17a** (80 mg, 0.21 mmol) was dissolved in DMF (10 mL), and freshly distilled BTMS (2 mL) was added. The reaction mixture was stirred overnight at r.t. under nitrogen. Excess solvents were removed under reduced pressure. The residue was dissolved in cold H₂O (1.5 mL), and acetone was added dropwise until a precipitate was formed. Recrystallization was carried out in H₂O/acetone to give a white solid (45 mg, 63%). MS (FAB): m/e 342 (M⁺+1), 340 (M⁺ -1). ¹H NMR (CD₃OD, 300 MHz): δ 7.38 (s, 1H, C8'H), 6.26–6.21 (m, 1H, C3H=C), 5.76–5.62 (m, 1H, C=C4H), 5.41 (d, 1H, C2H, J = 7 Hz), 3.88–3.72 (m, 2H, P[O]C H₂), 3.30–3.10 (m, 2H, C H₂OC), 2.81–2.68 (m, 1H, C1H), 2.54–2.28 (m, 2H, C5H₂). ³¹P NMR [(CD₃)₂SO, 300 MHz]: δ 19.50 ppm. Anal. calcd. (C₁₂H₁₆N₅O₅P.H₂O): C, 40.08; H, 5.05; N, 19.50; found: C, 40.24; H, 4.73; N, 19.68.

Cis- (\pm) -Methyl-2-[(2-amino-6-cyclopropylamino-9H-purin-9-yl) cyclopent-3-enylmethanol]-1-diethylphosphonate (18a)]

A suspension of 15 (400 mg, 1.4 mmol) and NaH (84 mg, 3.5 mmol) in anhydrous THF (35 mL) was stirred overnight at r.t. under nitrogen. The suspension was cooled to -20° C, and diethyl phosphonomethyl triflate (800 mg, 3 mmol) in THF (10 mL) was added dropwise. Stirring was continued at -20° C for 4 h and then at 4° C overnight. MeOH was added to quench the reaction, and solvent was removed under reduced pressure. The residue was chromatographed on a silica gel column to give slightly yellow oil (130 mg, 21%), $R_f = 0.56$ (CHCl₃:MeOH, 5:1). MS (FAB): m/e 437 (M⁺ +1). 1 H NMR [(CD₃)₂SO, 300 MHz]: δ 7.26 (s, 1H, C8'H), 6.20-6.18 (m, 1H, C3H=C), 6.00 (broad s, 1H, CHNcyclopropane), 5.77-5.75 (m, 1H, C=C4H), 5.50 (d, 1H, C2H, J = 7 Hz), 5.24 (s, 1H, NH), 5.10 (broad s, 2H, NH₂), 4.08-3.96 (m, 4H, OC H₂CH₃), 3.49-3.28 (m, 2H, P[O]C H₂), 3.22-3.03 (m, 2H, C H₂OC), 2.91-2.80 (m, 1H, C1H), 2.64–2.32 (m, 2H, C5H₂), 1.22 (dt, 6H, OCH₂C H₃, ${}^{4}J_{PH}=2$ Hz, ${}^{3}J_{HH} = 7$ Hz), 0.78–0.49 (m, 4H, CH₂CH₂). ${}^{31}P$ NMR, proton coupled [(CD₃)₂SO, 300 MHz]: δ 22.23 (m). Anal. calc'd. (C₁₉H₂₉N₆O₄P): C, 52.28; H, 6.70; N, 19.26; found: C, 51.89; H, 6.58; N, 19.20.

Cis-(\pm)-Methyl-2-[(2-amino-6-cyclopropylamino-9H-purin-9-yl) cyclopent-3-enylmethanol]-1-diethylphosphonic Acid (18b)

Diethyl phosphonate ester **18a** (120 mg, 0.28 mmol) was dissolved in CH₃CN (20 mL), and freshly distilled BTMS (1 mL) was added. The reaction mixture was stirred overnight at r.t. under nitrogen. Solvents were removed under reduced pressure, and the residue dissolved in cold $\rm H_2O$ (1.5 mL). Acetone was added dropwise until a precipitate was

formed. Recrystallization from $\rm H_2O$ /acetone gave a white solid (35 mg) in 33% yield, m.p. 232–234°C. MS (FAB): m/e 381 (M⁺ +1). ¹H NMR (CD₃OD, 300 MHz): δ 8.38, 8.27 (each s, each 1H, C8'H and C HN-), 6.25–6.20 (m, 1H, C3H=C), 5.70–5.68 (m, 1H, C=C4H), 5.51 (d, 1H, C2H, J=7 Hz), 3.68–3.62 (m, 2H, [PO]CH₂), 3.40–3.20 (m, 2H, C<u>H</u>₂OC), 2.91–2.78 (m, 1H, C1H), 2.50–2.25 (m, 2H, C5H₂), 0.99–0.68 (m, 4H, CH₂CH₂). ³¹P NMR [(CD₃)₂SO, 300 MHz]:δ 19.48 ppm.

Anal. calc'd. $(C_{15}H_{21}N_6O_4P.H_2O)$: C, 45.22; H, 5.82; N, 21.10; found: C, 45.28; H, 5.92; N, 21.29.

REFERENCES

- [1] J. R. Malpass and N. J. Tweddle, J.C.S. Perkin I, 874 (1977).
- [2] E. DeClercq, Intern. J. of Biochem. & Cell Bio., 36, 1800 (2004).
- [3] I. W. Leonard and E. K. Edward, Adv. Drug Delivery Rev., 39, 63 (1999).
- [4] R. Vince, M. Hua, J. Brownell, S. Daluge, F. Lee, W. M. Shannon et al. Biochem. Biophys. Res. Commun., 156, 1046 (1988).
- [5] R. Vince and M. Hua, J. Med. Chem., 33, 17 (1990).
- [6] B. A. Larder, J. Gen. Virol., 75, 951 (1994).
- [7] A. A. Johnson, A. S. Ray, J. Hanest, Z. Suo, J. M. Colacino, K. S. Anderson et al. J. of Biol. Chem., 276, 40847.
- [8] E. DeClercq, A. Holy, I. Rosenberg, T. Sakuma, J. Balzarini, and P. C. Maudgal, Nature, 323, 464 (1986).
- [9] J. Balzarini, C. F. Perno, D. Schols, and E. DeClerq, Biochem. & Biophys. Res. Comm., 178, 329 (1991).
- [10] P. Herdewijn, C. Pannecouque, T. Wu, and E. DeClercq, U.S. Patent 2004-552730 20,040,315; PCT Int. Appl., 134 (2005).
- [11] J. C. Jagt and A. M. Van Leusen, J. Org. Chem., 39, 564 (1974).
- [12] R. Vince, R. H. Turakhia, W. M. Shannon, and G. Arnett, J. Med. Chem., 30, 2026 (1987).
- [13] C. S. Kraihanzel, J. M. Ressner, and G. M. Gray, Inorg. Chem., 21, 879 (1982).
- [14] D. P. Phillion and S. S. Andrew, Tet. Lett., 27, 1477 (1986).